GlaxoSmithKline Pharmaceuticals Limited Share Price & Analysis
₹2,506.6▲ +0.95%Updated 21 Jul 2026, 05:01 pm IST
LTP
₹2,506.6
+0.95%
Open
₹—
High
₹2,510
Low
₹2,465.2
Close
₹2,506.6
52W High
₹3,220
52W Low
₹2,088
Volume
41K
Lot Size
1
Sector
Healthcare
Market Cap
₹42K Cr
Face Value
₹10
Large CapNIFTY 500
Price Chart
Fundamentals
P/E
43.2
Sector P/E
54.4
P/B
16.36
EPS
₹60.18
ROE
45.6%
ROCE
61.4%
D/E Ratio
0.01
Div Yield
2.32%
Book Value
₹134
+
Strengths
- ✓Excellent return on equity (ROE 45.6%)
- ✓Efficient capital deployment (ROCE 61.4%)
- ✓Attractively valued vs sector (P/E 43.2x vs industry 54.4x)
- ✓Virtually debt-free
- ✓Regular dividends — yield 2.3%
−
Concerns
- ✗High premium to book value (P/B 16.4x)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,944 | ₹4.6L Cr | 37.3 | 5.59 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹7,388 | ₹1.9L Cr | 73.4 | 11.71 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹5,040 | ₹1.6L Cr | 73.6 | 20.32 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,939 | ₹1.3L Cr | 64.9 | 13.56 | 22.1 | 17.9 | 0.88 |
| CIPLA Cipla Limited | ₹1,416 | ₹1.1L Cr | 30.1 | 3.32 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,123 | ₹1.1L Cr | 21 | 4.17 | 21.2 | 21.1 | 0.38 |
| LUPIN Lupin Limited | ₹2,405 | ₹1.1L Cr | 19.6 | 4.9 | 28.7 | 29.9 | 0.32 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
GLAXO · as of Mar 2026
Promoters75.00%
FII4.52%▲0.02
DII7.79%▲0.49
Public12.69%▼0.52
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% |
| FII | 2.93% | 3.48% | 4.02% | 4.36% | 4.50% | 4.52% |
| DII | 8.64% | 7.90% | 7.51% | 7.34% | 7.30% | 7.79% |
| Public | 13.42% | 13.62% | 13.48% | 13.30% | 13.21% | 12.69% |
| Govt | 0.01% | — | — | — | — | — |
Corporate Events
To consider and approve the financial results for the period ended Jun 30, 2026
Results2 Aug 2026
Dividend - Rs 57 Per Share
Dividend28 May 2026
Dividend - Rs 42 Per Share
Dividend29 May 2025
Interim Dividend - Rs 12 Per Share
Dividend6 Nov 2024
Dividend - Rs 32 Per Share
Dividend30 May 2024
Dividend - Rs 32 Per Share
Dividend29 Jun 2023
Latest News
All news →Financials
Quarterly Results
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹995 Cr ▼4.4% | ₹1.0K Cr ▲6.2% | ₹980 Cr ▲21.7% | ₹805 Cr ▼17.4% | ₹974 Cr ▲2.6% | ₹949 Cr ▼6.1% | ₹1.0K Cr ▲24.0% | ₹815 Cr |
| Op. Profit | ₹351 Cr ▼5.4% | ₹371 Cr ▲10.4% | ₹336 Cr ▲33.9% | ₹251 Cr ▼24.6% | ₹333 Cr ▲14.0% | ₹292 Cr ▼9.3% | ₹322 Cr ▲39.4% | ₹231 Cr |
| OPM | 35.0% ▼2.8% | 36.0% ▲5.9% | 34.0% ▲9.7% | 31.0% ▼8.8% | 34.0% ▲9.7% | 31.0% ▼3.1% | 32.0% ▲14.3% | 28.0% |
| Net Profit | ₹278 Cr ▼6.1% | ₹296 Cr ▲15.2% | ₹257 Cr ▲25.4% | ₹205 Cr ▼22.1% | ₹263 Cr ▲14.3% | ₹230 Cr ▼8.7% | ₹252 Cr ▲38.5% | ₹182 Cr |
| EPS (₹) | 16.4 ▼6.0% | 17.45 ▲14.8% | 15.2 ▲25.6% | 12.1 ▼22.0% | 15.52 ▲14.4% | 13.57 ▼9.0% | 14.91 ▲38.6% | 10.76 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3.8K Cr ▲1.9% | ₹3.7K Cr ▲8.5% | ₹3.5K Cr ▲6.2% | ₹3.3K Cr ▼0.8% | ₹3.3K Cr ▲12.0% | ₹2.9K Cr ▼9.2% | ₹3.2K Cr ▲3.1% | ₹3.1K Cr ▲9.0% | ₹2.9K Cr ▼1.3% | ₹2.9K Cr |
| Expenses | ₹2.5K Cr ▼2.3% | ₹2.6K Cr ▲1.0% | ₹2.5K Cr ▲4.0% | ₹2.4K Cr ▼2.7% | ₹2.5K Cr ▲8.1% | ₹2.3K Cr ▼9.3% | ₹2.6K Cr ▲1.6% | ₹2.5K Cr ▲6.9% | ₹2.4K Cr ▼5.1% | ₹2.5K Cr |
| Op. Profit | ₹1.3K Cr ▲11.0% | ₹1.2K Cr ▲29.7% | ₹909 Cr ▲13.1% | ₹804 Cr ▲5.5% | ₹762 Cr ▲27.4% | ₹598 Cr ▼9.0% | ₹657 Cr ▲9.3% | ₹601 Cr ▲18.3% | ₹508 Cr ▲21.0% | ₹420 Cr |
| OPM | 34.0% ▲9.7% | 31.0% ▲19.2% | 26.0% ▲4.0% | 25.0% ▲8.7% | 23.0% ▲15.0% | 20.0% ▲0.0% | 20.0% ▲5.3% | 19.0% ▲5.6% | 18.0% ▲28.6% | 14.0% |
| Other Income | ₹166 Cr ▲11.4% | ₹149 Cr ▲809.5% | ₹-21 Cr ▼120.4% | ₹103 Cr ▼92.6% | ₹1.4K Cr ▲15466.7% | ₹9 Cr ▲103.4% | ₹-262 Cr ▼300.0% | ₹131 Cr ▲87.1% | ₹70 Cr ▼41.2% | ₹119 Cr |
| Interest | ₹3 Cr ▲200.0% | ₹1 Cr ▼50.0% | ₹2 Cr ▲0.0% | ₹2 Cr ▲0.0% | ₹2 Cr ▼50.0% | ₹4 Cr ▼33.3% | ₹6 Cr ▲500.0% | ₹1 Cr | ₹0 Cr | ₹0 Cr |
| Depreciation | ₹66 Cr ▼1.5% | ₹67 Cr ▼4.3% | ₹70 Cr ▲6.1% | ₹66 Cr ▼2.9% | ₹68 Cr ▼13.9% | ₹79 Cr ▼4.8% | ₹83 Cr ▲69.4% | ₹49 Cr ▲28.9% | ₹38 Cr ▲40.7% | ₹27 Cr |
| PBT | ₹1.4K Cr ▲11.6% | ₹1.3K Cr ▲54.4% | ₹816 Cr ▼2.7% | ₹839 Cr ▼59.9% | ₹2.1K Cr ▲298.7% | ₹525 Cr ▲71.6% | ₹306 Cr ▼55.2% | ₹683 Cr ▲26.5% | ₹540 Cr ▲5.7% | ₹511 Cr |
| Tax % | 26.0% ▲0.0% | 26.0% ▼7.1% | 28.0% ▲3.7% | 27.0% ▲42.1% | 19.0% ▼40.6% | 32.0% ▼54.3% | 70.0% ▲100.0% | 35.0% ▲0.0% | 35.0% ▲2.9% | 34.0% |
| Net Profit | ₹1.0K Cr ▲11.6% | ₹928 Cr ▲57.3% | ₹590 Cr ▼3.4% | ₹611 Cr ▼64.0% | ₹1.7K Cr ▲373.5% | ₹358 Cr ▲284.9% | ₹93 Cr ▼79.1% | ₹445 Cr ▲26.8% | ₹351 Cr ▲4.2% | ₹337 Cr |
| EPS (₹) | 61.15 ▲11.7% | 54.75 ▲57.2% | 34.83 ▼3.4% | 36.05 ▼64.0% | 100.04 ▲373.2% | 21.14 ▲284.4% | 5.5 ▼79.1% | 26.29 ▲27.0% | 20.7 ▲4.1% | 19.88 |
| Div Payout | 93.0% ▼6.1% | 99.0% ▲7.6% | 92.0% ▲3.4% | 89.0% ▼1.1% | 90.0% ▼36.6% | 142.0% ▼80.5% | 727.0% ▲856.6% | 76.0% ▼10.6% | 85.0% ▲13.3% | 75.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | ||||||||||
| Equity Capital | ₹169 Cr ▲0.0% | ₹169 Cr ▲0.0% | ₹169 Cr ▲0.0% | ₹169 Cr ▲0.0% | ₹169 Cr ▲0.0% | ₹169 Cr ▲0.0% | ₹169 Cr ▲0.0% | ₹169 Cr ▲98.8% | ₹85 Cr ▲0.0% | ₹85 Cr |
| Reserves | ₹2.1K Cr ▲17.7% | ₹1.8K Cr ▲10.8% | ₹1.6K Cr ▲2.3% | ₹1.6K Cr ▼37.0% | ₹2.5K Cr ▲90.5% | ₹1.3K Cr ▼20.7% | ₹1.7K Cr ▼16.2% | ₹2.0K Cr ▼0.2% | ₹2.0K Cr ▲2.7% | ₹1.9K Cr |
| Borrowings | ₹33 Cr ▲230.0% | ₹10 Cr ▼47.4% | ₹19 Cr ▲18.8% | ₹16 Cr ▼20.0% | ₹20 Cr ▼42.9% | ₹35 Cr | ₹0 Cr ▼100.0% | ₹1 Cr ▲0.0% | ₹1 Cr ▼50.0% | ₹2 Cr |
| Other Liabilities | ₹2.0K Cr ▼5.8% | ₹2.1K Cr ▲22.0% | ₹1.8K Cr ▲12.1% | ₹1.6K Cr ▼19.5% | ₹1.9K Cr ▲21.7% | ₹1.6K Cr ▲21.8% | ₹1.3K Cr ▼25.7% | ₹1.8K Cr ▼6.2% | ₹1.9K Cr ▲89.8% | ₹995 Cr |
| Total Liabilities | ₹4.3K Cr ▲5.3% | ₹4.1K Cr ▲15.5% | ₹3.6K Cr ▲6.9% | ₹3.3K Cr ▼28.2% | ₹4.6K Cr ▲48.7% | ₹3.1K Cr ▼0.7% | ₹3.1K Cr ▼19.8% | ₹3.9K Cr ▼0.9% | ₹3.9K Cr ▲31.4% | ₹3.0K Cr |
| Assets | ||||||||||
| Fixed Assets | ₹281 Cr ▼1.1% | ₹284 Cr ▼11.5% | ₹321 Cr ▼2.7% | ₹330 Cr ▼0.3% | ₹331 Cr ▼14.5% | ₹387 Cr ▼48.9% | ₹758 Cr ▲75.5% | ₹432 Cr ▲32.9% | ₹325 Cr ▲26.0% | ₹258 Cr |
| CWIP | ₹33 Cr ▲135.7% | ₹14 Cr ▲0.0% | ₹14 Cr ▼30.0% | ₹20 Cr ▼33.3% | ₹30 Cr ▲130.8% | ₹13 Cr ▼89.2% | ₹120 Cr ▼88.0% | ₹1.0K Cr ▲8.7% | ₹923 Cr ▲52.6% | ₹605 Cr |
| Investments | ₹1.4K Cr ▲24.5% | ₹1.1K Cr ▲37.5% | ₹813 Cr ▲56.9% | ₹518 Cr ▲41.5% | ₹366 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other Assets | ₹2.6K Cr ▼2.7% | ₹2.7K Cr ▲11.8% | ₹2.4K Cr ▼2.0% | ₹2.5K Cr ▼37.1% | ₹3.9K Cr ▲43.9% | ₹2.7K Cr ▲20.3% | ₹2.3K Cr ▼8.9% | ₹2.5K Cr ▼8.3% | ₹2.7K Cr ▲26.2% | ₹2.1K Cr |
| Total Assets | ₹4.3K Cr ▲5.3% | ₹4.1K Cr ▲15.5% | ₹3.6K Cr ▲6.9% | ₹3.3K Cr ▼28.2% | ₹4.6K Cr ▲48.7% | ₹3.1K Cr ▼0.7% | ₹3.1K Cr ▼19.8% | ₹3.9K Cr ▼0.9% | ₹3.9K Cr ▲31.4% | ₹3.0K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹903 Cr ▼30.0% | ₹1.3K Cr ▲121.6% | ₹582 Cr ▲20.2% | ₹484 Cr ▼40.3% | ₹811 Cr ▲40.3% | ₹578 Cr ▲18.0% | ₹490 Cr ▲19.8% | ₹409 Cr ▼13.5% | ₹473 Cr ▲102.1% | ₹234 Cr |
| Investing CF | ₹397 Cr ▲963.0% | ₹-46 Cr ▼611.1% | ₹9 Cr ▼98.9% | ₹808 Cr ▲299.0% | ₹-406 Cr ▼197.1% | ₹418 Cr ▲833.3% | ₹-57 Cr ▲62.7% | ₹-153 Cr ▼47.1% | ₹-104 Cr ▼134.6% | ₹301 Cr |
| Financing CF | ₹-737 Cr ▲4.2% | ₹-769 Cr ▼36.8% | ₹-562 Cr ▲63.6% | ₹-1.5K Cr ▼194.5% | ₹-524 Cr ▲24.7% | ₹-696 Cr ▼62.6% | ₹-428 Cr ▼19.6% | ₹-358 Cr ▼16.6% | ₹-307 Cr ▲39.9% | ₹-511 Cr |
| Net Cash Flow | ₹563 Cr ▲18.5% | ₹475 Cr ▲1537.9% | ₹29 Cr ▲111.6% | ₹-251 Cr ▼110.9% | ₹-119 Cr ▼139.7% | ₹300 Cr ▲4900.0% | ₹6 Cr ▲105.9% | ₹-102 Cr ▼264.5% | ₹62 Cr ▲158.3% | ₹24 Cr |
| Free Cash Flow | ₹870 Cr ▼31.7% | ₹1.3K Cr ▲122.2% | ₹573 Cr ▲27.1% | ₹451 Cr ▼81.0% | ₹2.4K Cr ▲342.4% | ₹536 Cr ▲59.5% | ₹336 Cr ▲102.4% | ₹166 Cr ▼74.0% | ₹639 Cr ▲2762.5% | ₹-24 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 26d ▼7.1% | 28d ▲21.7% | 23d ▲4.5% | 22d ▼4.3% | 23d ▼14.8% | 27d ▲145.5% | 11d ▼21.4% | 14d ▼26.3% | 19d ▼9.5% | 21d |
| Inventory Days | 124d ▼1.6% | 126d ▼12.5% | 144d ▲9.9% | 131d ▼9.0% | 144d ▼9.4% | 159d ▲17.8% | 135d ▲3.1% | 131d ▼10.9% | 147d ▲32.4% | 111d |
| Days Payable | 154d ▼17.2% | 186d ▲8.8% | 171d ▲40.2% | 122d ▼21.8% | 156d ▲15.6% | 135d ▲35.0% | 100d ▼8.3% | 109d ▼26.8% | 149d ▲104.1% | 73d |
| Cash Conv. Cycle | -4d ▲87.1% | -31d ▼675.0% | -4d ▼112.9% | 31d ▲181.8% | 11d ▼78.0% | 50d ▲8.7% | 46d ▲27.8% | 36d ▲111.8% | 17d ▼71.7% | 60d |
| Working Capital Days | -91d ▲8.1% | -99d ▼54.7% | -64d ▼12.3% | -57d ▲39.4% | -94d ▼141.0% | -39d ▼2.6% | -38d ▲47.2% | -72d ▲20.0% | -90d ▼1385.7% | 7d |
| ROCE | 61.0% ▼3.2% | 63.0% ▲23.5% | 51.0% ▲41.7% | 36.0% ▼2.7% | 37.0% ▼2.6% | 38.0% ▲15.2% | 33.0% ▲6.5% | 31.0% ▲19.2% | 26.0% ▲18.2% | 22.0% |
Source: Screener.in · Lower days = better efficiency
About GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site)
Healthcare · Pharmaceuticals & Biotechnology
Related Analysis
Frequently Asked Questions
What is GlaxoSmithKline Pharmaceuticals Limited share price today?▾
GlaxoSmithKline Pharmaceuticals Limited (GLAXO) is currently trading at ₹2,506.6 on NSE, up 0.95% as of the last market session. Prices update daily after market close on MarketNetra.
Is GlaxoSmithKline Pharmaceuticals Limited available in F&O (Futures & Options)?▾
Yes, GlaxoSmithKline Pharmaceuticals Limited (GLAXO) is part of the NSE F&O segment with a lot size of 1 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is GlaxoSmithKline Pharmaceuticals Limited 52-week high and low?▾
GlaxoSmithKline Pharmaceuticals Limited's 52-week high is ₹3,220 and the 52-week low is ₹2,088. The current price of ₹2,506.6 is 22.2% below the 52W high.
What is GlaxoSmithKline Pharmaceuticals Limited P/E ratio?▾
GlaxoSmithKline Pharmaceuticals Limited's current P/E ratio is 43.2. This indicates the market is paying ₹43.2 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade GlaxoSmithKline Pharmaceuticals Limited options?▾
GlaxoSmithKline Pharmaceuticals Limited options are traded on NSE with monthly expiry contracts (lot size: 1 shares). To trade GLAXO options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.